2012 Fiscal Year Final Research Report
Developing of polymeric micelle for molecular targeting to cancer stem cells in ovarian cancer patients.
| Project/Area Number |
22659303
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TERAI Yoshito 大阪医科大学, 医学部, 講師 (90278531)
TANABE Akiko 大阪医科大学, 医学部, 助教 (70454543)
KANEMURA Masanori 大阪医科大学, 医学部, 講師 (40298782)
SASAKI Hiroshi 大阪医科大学, 医学部, 助教 (80432491)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | CD24, 婦人科悪性腫瘍 / 上皮間葉形質転換 / EMT, 高分子ミセル / 抗癌剤耐性 |
|---|
| Research Abstract |
The epithelial-mesenchymal-transition (EMT) is an important step in the invasion and metastasis of cancer cells. EMT is an important step in the invasion and metastasis of cancer. G protein-coupled receptor 30 (GPR30) is a 7-transmembrane estrogen receptor that functions alongside traditional estrogen receptors to regulate the cellular responses to estrogen. Current study suggested that the expression of both GPR30 and EGFR is associated with a poor outcome in ovarian cancer, and GPR30 increases the phosphorylation of Akt via the EGFR in ovarian cancer cells. The regulation of GPR30 might be a potentially useful new therapeutic target in ovarian cancer. Furthermore, Recently CD24 has been considered as a prognostic maker in various cancers. So we analyzed the prognostic impact of the CD24 expression in ovarian cancer by immunostaining. The CD24 expression was significantly associated with FIGO stage, lymph node metastasis and peritoneal metastasis. The in vitro examination showedthat high expression level of CD24 is significantly associated with EMT positivity. In addition, the CD24 overexpression increased invasiveness, and knockdown of CD24 suppressed cell invasion. In conclusion CD24 expression in ovarian cancer may be related to tumor invasion and migration. Based on the results, the anti-cancer agent incorporated polymeric micelles, which have anti-GPR30 or anti-CD24 antibodies in their outer layer, are in development
|
